UPLOAD Filing
BridgeBio Oncology Therapeutics, Inc.
Date: June 27, 2025 · CIK: 0001869105 · Accession: 0000000000-25-006779
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288222
Letter
June 27, 2025 Bihua Chen Chief Executive Officer Helix Acquisition Corp. II 200 Clarendon Street, 52nd Floor Boston, MA 02116 Eli Wallace Chief Executive Officer TheRas, Inc. 256 E. Grand Avenue, Suite 104 South San Francisco, CA 94080 Re:Helix Acquisition Corp. II TheRas, Inc. Registration Statement on Form S-4 Filed June 20, 2025 File No. 333-288222 Dear Bihua Chen and Eli Wallace: We have reviewed your registration statement and have the following comments. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Registration Statement on Form S-4 Dilution, page 236 We note the revisions to your Dilution disclosure in response to prior comment one. Your revised NTBV calculation removes the adjustment to reflect the "conversion of Helix equity into equity of combined company" which was not the intent of our prior comment. Although the effects of the Business Combination itself should be excluded from the dilution disclosures, the lapse of redemption provisions 1.
June 27, 2025 Page 2 after consummation of the Business Combination will result in such shares being reclassified to permanent equity. As such, it would appear that the value of such shares (after reflecting redemptions) should be included in your NTBV calculation. Further, your current NTBV per share calculation includes these shares in the denominator but excludes the value of such shares from the numerator. Please revise accordingly. TheRas, Inc. - Notes to Unaudited Condensed Financial Statements 5. Commitments and Contingencies, page F-56 2.We note your disclosure on page 300 of the April 2025 dispute over indexed milestone payments from the terminated UCSF license agreement and your disclosure on pages F-56 and F-82 that " [TheRas] is not currently involved in any legal actions that could have a material effect on the Company's financial position, results of operations, or liquidity." Please tell us your consideration of providing the disclosures required by ASC 450-20-50-3 through 50-5 as it relates to this potential loss contingency, including the amount or range of reasonably possible losses in excess of recorded amounts. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Bonnie Baynes at 202-551-4924 or Angela Connell at 202-551-3426 if you have questions regarding comments on the financial statements and related matters. Please contact Tyler Howes at 202-551-3370 or Joshua Gorsky at 202-551-7836 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Joel Rubinstein, Esq. Maggie L. Wong, Esq.
Show Raw Text
June 27, 2025
Bihua Chen
Chief Executive Officer
Helix Acquisition Corp. II
200 Clarendon Street, 52nd Floor
Boston, MA 02116
Eli Wallace
Chief Executive Officer
TheRas, Inc.
256 E. Grand Avenue, Suite 104
South San Francisco, CA 94080
Re:Helix Acquisition Corp. II
TheRas, Inc.
Registration Statement on Form S-4
Filed June 20, 2025
File No. 333-288222
Dear Bihua Chen and Eli Wallace:
We have reviewed your registration statement and have the following comments.
Please respond to this letter by amending your registration statement and providing
the requested information. If you do not believe a comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information
you provide in response to this letter, we may have additional comments.
Registration Statement on Form S-4
Dilution, page 236
We note the revisions to your Dilution disclosure in response to prior comment
one. Your revised NTBV calculation removes the adjustment to reflect the
"conversion of Helix equity into equity of combined company" which was not the
intent of our prior comment. Although the effects of the Business Combination itself
should be excluded from the dilution disclosures, the lapse of redemption provisions 1.
June 27, 2025
Page 2
after consummation of the Business Combination will result in such shares being
reclassified to permanent equity. As such, it would appear that the value of such
shares (after reflecting redemptions) should be included in your NTBV
calculation. Further, your current NTBV per share calculation includes these shares in
the denominator but excludes the value of such shares from the numerator. Please
revise accordingly.
TheRas, Inc. - Notes to Unaudited Condensed Financial Statements
5. Commitments and Contingencies, page F-56
2.We note your disclosure on page 300 of the April 2025 dispute over indexed
milestone payments from the terminated UCSF license agreement and your disclosure
on pages F-56 and F-82 that " [TheRas] is not currently involved in any legal actions
that could have a material effect on the Company's financial position, results of
operations, or liquidity." Please tell us your consideration of providing the disclosures
required by ASC 450-20-50-3 through 50-5 as it relates to this potential loss
contingency, including the amount or range of reasonably possible losses in excess of
recorded amounts.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence
of action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Bonnie Baynes at 202-551-4924 or Angela Connell at 202-551-3426 if
you have questions regarding comments on the financial statements and related
matters. Please contact Tyler Howes at 202-551-3370 or Joshua Gorsky at 202-551-7836
with any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Joel Rubinstein, Esq.
Maggie L. Wong, Esq.